$DARE
Dare Bioscience, Inc.

2021 Q1 Form 10-Q Financial Statement

#000140191421000080 Filed on May 13, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.970M $1.870M
YoY Change 5.35% 34.53%
% of Gross Profit
Research & Development $5.728M $2.380M
YoY Change 140.7% 40.53%
% of Gross Profit
Depreciation & Amortization $6.410K $11.95K
YoY Change -46.36% 939.04%
% of Gross Profit
Operating Expenses $7.694M $4.254M
YoY Change 80.85% 37.98%
Operating Profit -$7.694M -$4.254M
YoY Change 80.85% 37.98%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $3.00 $1.821K
YoY Change -99.84% -94.17%
Pretax Income -$7.320M -$4.250M
YoY Change 72.24% 39.34%
Income Tax
% Of Pretax Income
Net Earnings -$7.324M -$4.252M
YoY Change 72.23% 39.33%
Net Earnings / Revenue
Basic Earnings Per Share -$0.16
Diluted Earnings Per Share -$0.16 -$178.6K
COMMON SHARES
Basic Shares Outstanding 44.50M shares 24.69M shares
Diluted Shares Outstanding 44.50M shares

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.660M $5.050M
YoY Change 51.68% 43.87%
Cash & Equivalents $7.660M $5.047M
Short-Term Investments
Other Short-Term Assets $1.640M $3.840M
YoY Change -57.29% 550.85%
Inventory
Prepaid Expenses $1.637M $3.845M
Receivables
Other Receivables $301.8K $429.7K
Total Short-Term Assets $9.599M $9.322M
YoY Change 2.97% 118.81%
LONG-TERM ASSETS
Property, Plant & Equipment $31.52K $51.58K
YoY Change -38.89% 525.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $887.9K $840.6K
YoY Change 5.63% 11.88%
Total Long-Term Assets $919.4K $892.2K
YoY Change 3.05% 17.45%
TOTAL ASSETS
Total Short-Term Assets $9.599M $9.322M
Total Long-Term Assets $919.4K $892.2K
Total Assets $10.52M $10.21M
YoY Change 2.98% 103.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.472M $1.531M
YoY Change -3.91% 364.09%
Accrued Expenses $2.520M $1.691M
YoY Change 49.05% 144.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.108M $4.716M
YoY Change 29.54% 363.93%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.150M $284.2K
YoY Change 304.64% 27.42%
Total Long-Term Liabilities $1.150M $284.2K
YoY Change 304.64% 27.42%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.108M $4.716M
Total Long-Term Liabilities $1.150M $284.2K
Total Liabilities $7.260M $7.000M
YoY Change 3.72% 464.73%
SHAREHOLDERS EQUITY
Retained Earnings -$78.80M -$48.30M
YoY Change 63.15% 50.84%
Common Stock $82.11M $51.62M
YoY Change 59.08% 43.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.258M $3.214M
YoY Change
Total Liabilities & Shareholders Equity $10.52M $10.21M
YoY Change 2.98% 103.47%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$7.324M -$4.252M
YoY Change 72.23% 39.33%
Depreciation, Depletion And Amortization $6.410K $11.95K
YoY Change -46.36% 939.04%
Cash From Operating Activities -$8.377M -$6.598M
YoY Change 26.97% 99.41%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $11.37M $6.888M
YoY Change 65.14%
NET CHANGE
Cash From Operating Activities -$8.377M -$6.598M
Cash From Investing Activities $0.00
Cash From Financing Activities $11.37M $6.888M
Net Change In Cash $2.991M $267.2K
YoY Change 1019.19% -108.1%
FREE CASH FLOW
Cash From Operating Activities -$8.377M -$6.598M
Capital Expenditures $0.00
Free Cash Flow -$8.377M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001401914
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2021Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2021Q1 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
DARÉ BIOSCIENCE, INC.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity File Number
EntityFileNumber
001-36395
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-4139823
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 260
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1637089 USD
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3655 Nobel Drive
CY2020Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
460168 USD
CY2021Q1 dei City Area Code
CityAreaCode
858
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
926-7655
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92122
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2021Q1 dei Trading Symbol
TradingSymbol
DARE
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
49350077 shares
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7660151 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4669467 USD
CY2021Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
301835 USD
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1854277 USD
CY2021Q1 us-gaap Assets Current
AssetsCurrent
9599075 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
6983912 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
31520 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37930 USD
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
887858 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
528870 USD
CY2021Q1 us-gaap Assets
Assets
10518453 USD
CY2020Q4 us-gaap Assets
Assets
7550712 USD
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1471631 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1021333 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2519925 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3359718 USD
CY2021Q1 dare Deferred Grant Funding Current
DeferredGrantFundingCurrent
672430 USD
CY2020Q4 dare Deferred Grant Funding Current
DeferredGrantFundingCurrent
1564553 USD
CY2021Q1 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
367285 USD
CY2021Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
1000000 USD
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
1000000 USD
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
444448 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
347712 USD
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
6108434 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7660601 USD
CY2021Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1000000 USD
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1000000 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
151786 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
41844 USD
CY2021Q1 us-gaap Liabilities
Liabilities
7260220 USD
CY2020Q4 us-gaap Liabilities
Liabilities
8702445 USD
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47312822 shares
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47312822 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41596253 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41596253 shares
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
4731 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
4159 USD
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-98229 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-91388 USD
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
82106172 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
70366293 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-78754441 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-71430797 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
3258233 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-1151733 USD
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10518453 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7550712 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1940328 USD
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1861765 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5728206 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2379804 USD
CY2021Q1 dare License Fee
LicenseFee
25000 USD
CY2020Q1 dare License Fee
LicenseFee
12500 USD
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
7693534 USD
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
4254069 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7693534 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4254069 USD
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1821 USD
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
369887 USD
CY2020Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7323644 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4252248 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-6841 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-22944 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7330485 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4275192 USD
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44502582 shares
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23799396 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-1151733 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
365911 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11324140 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
50400 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7323644 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7323644 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-6841 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1665020 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
3258233 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
440826 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
160841 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5222687 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4252248 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-22944 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
3214183 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7323644 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4252248 USD
CY2021Q1 us-gaap Depreciation
Depreciation
6410 USD
CY2020Q1 us-gaap Depreciation
Depreciation
11949 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
365911 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
160841 USD
CY2021Q1 dare Non Cash Lease Expense
NonCashLeaseExpense
-24224 USD
CY2020Q1 dare Non Cash Lease Expense
NonCashLeaseExpense
-55786 USD
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
369887 USD
CY2020Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2021Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-158333 USD
CY2020Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-125488 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-217188 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2736149 USD
CY2021Q1 dare Increase Decrease In Other Non Current Assets And Deferred Charges
IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges
128086 USD
CY2020Q1 dare Increase Decrease In Other Non Current Assets And Deferred Charges
IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges
-38682 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
450298 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
448314 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-837191 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-408027 USD
CY2021Q1 dare Increase Decrease In Deferred Grant Funding
IncreaseDecreaseInDeferredGrantFunding
892123 USD
CY2020Q1 dare Increase Decrease In Deferred Grant Funding
IncreaseDecreaseInDeferredGrantFunding
930610 USD
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 USD
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1000000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8377015 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6597546 USD
CY2021Q1 dare Net Proceeds From Issuance Of Common Stock And Warrants
NetProceedsFromIssuanceOfCommonStockAndWarrants
11324140 USD
CY2020Q1 dare Net Proceeds From Issuance Of Common Stock And Warrants
NetProceedsFromIssuanceOfCommonStockAndWarrants
5222687 USD
CY2021Q1 dare Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
50400 USD
CY2020Q1 dare Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
1665020 USD
CY2021Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
CY2020Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11374540 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6887708 USD
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-6841 USD
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-22944 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2990684 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
267218 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4669467 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7660151 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5047325 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4780107 USD
CY2021Q1 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
369887 USD
CY2020Q1 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
0 USD
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
308533 USD
CY2020Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-78800000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7700000 USD
CY2021Q1 dare Working Capital Increase Deficit
WorkingCapitalIncreaseDeficit
3500000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7300000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
8400000 USD
CY2021Q1 dare Periodof Insufficient Cashand Liquidity Requirements
PeriodofInsufficientCashandLiquidityRequirements
P12M
CY2018Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.07
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
444000 USD
CY2021Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2021Q1 us-gaap Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
4651245 USD
CY2021Q1 dare Weighted Average Amortization Period
WeightedAverageAmortizationPeriod
P3Y4M28D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0058
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.22
CY2021Q1 dare Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
0.000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.25
CY2020Q2 dare Saleof Stock Maximum Amount Registered
SaleofStockMaximumAmountRegistered
7500000 shares
CY2021Q1 dare Saleof Stock Maximum Amount Registered
SaleofStockMaximumAmountRegistered
6400000 shares
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.00
CY2019Q2 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
0.98
CY2020Q3 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
0.96
CY2019Q2 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
800000 USD
CY2020Q3 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
6863 USD
CY2021Q1 dare Number Of Common Stock Warrants Exercised
NumberOfCommonStockWarrantsExercised
52500 shares
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
50000 USD
CY2020Q1 dare Number Of Common Stock Warrants Exercised
NumberOfCommonStockWarrantsExercised
1699000 shares
CY2020Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1700000 USD
CY2021Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1856143 shares
CY2018Q3 us-gaap Net Rentable Area
NetRentableArea
3169 sqft
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
112000 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
152000 USD
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
135000 USD
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
99000 USD
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
128000 USD
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M21D
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
349000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
278000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
627000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
31000 USD
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
596000 USD
CY2021Q1 dare Deferred Grant Funding Current
DeferredGrantFundingCurrent
700000 USD
CY2020Q2 dare Coronavirus Aid Reliefand Economic Security Act Loan Proceeds Received
CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived
367285 USD
CY2021Q1 dare Notes Payable Current Plus Accrued Interest
NotesPayableCurrentPlusAccruedInterest
369887 USD
CY2018 dare Proceeds From Award Of Grant
ProceedsFromAwardOfGrant
1900000 USD
CY2020Q2 dare Proceeds From Award Of Grant
ProceedsFromAwardOfGrant
731000 USD
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6167434 shares
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4621269 shares

Files In Submission

Name View Source Status
0001401914-21-000080-index-headers.html Edgar Link pending
0001401914-21-000080-index.html Edgar Link pending
0001401914-21-000080.txt Edgar Link pending
0001401914-21-000080-xbrl.zip Edgar Link pending
dare-20210331.htm Edgar Link pending
dare-20210331.xsd Edgar Link pending
dare-20210331_cal.xml Edgar Link unprocessable
dare-20210331_def.xml Edgar Link unprocessable
dare-20210331_g1.jpg Edgar Link pending
dare-20210331_htm.xml Edgar Link completed
dare-20210331_lab.xml Edgar Link unprocessable
dare-20210331_pre.xml Edgar Link unprocessable
exhibit311_20210331.htm Edgar Link pending
exhibit312_20210331.htm Edgar Link pending
exhibit321_20210331.htm Edgar Link pending
exhibit322_20210331.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending